Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Afatinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 31 May 2016 Status changed from active, no longer recruiting to completed.
- 09 Oct 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 15 May 2013 Planned end date changed from 1 Mar 2012 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History